Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea

BACKGROUND: Irritable bowel syndrome with diarrhea (IBS-D) has limited options for treatment currently, including mainly anti-motility medications, antispasmodics, and antidepressants. This review discusses the properties of a new drug, eluxadoline, a gut-targeting mu- and kappa-opioid receptor agon...

Descripción completa

Detalles Bibliográficos
Autor principal: Fragkos, Konstantinos C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624596/
https://www.ncbi.nlm.nih.gov/pubmed/28989282
http://dx.doi.org/10.2147/CEG.S123621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624596/
https://www.ncbi.nlm.nih.gov/pubmed/28989282
http://dx.doi.org/10.2147/CEG.S123621

Ejemplares similares